As the film tells it, the story of this mural is also that of the crisis at Rikers and of “prison” in spectacular decay — ...

LOS ANGELES, Jan. 28, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Kyverna ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to Kyverna's initial public ...

NEW YORK, Jan. 23, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kyverna Therapeutics, Inc. ("Kyverna" or the ...

NEW YORK, Jan. 23, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX). Shareholders who purchased shares of KYTX ...

Analysts on Wall Street project that Hope Bancorp (HOPE) will announce quarterly earnings of $0.19 per share in its forthcoming report, representing a decline of 40.6% year over year. Revenues are ...

(RTTNews) - Kyverna Therapeutics, Inc. (KYTX) a California-based biopharmaceutical company, Tuesday announced the appointment of Naji Gehchan as Chief Medical and Development Officer. Gehchan will ...

Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to execute Company's next wave of ...

EMERYVILLE, Calif. - Kyverna Therapeutics Inc. (NASDAQ: KYTX), a clinical-stage biopharmaceutical company with a market capitalization of $144 million, today announced the appointment of Dr. Naji ...

Kyverna Therapeutics (KYTX) announced the appointment of Naji Gehchan, to Chief Medical and Development Officer, where he will lead the Company’s research, clinical development, and medical ...